yvonne greenstreet  glaxosmithkline plc  zoominfocom dr yvonne greenstreet joins pfizer as senior vice president and head of medicines development specialty care business unit  business wire dr yvonne greenstreet joins pfizer as senior vice president and head of medicines development specialty care business unit download full size small preview thumbnail dr yvonne greenstreet photo business wire paginationprevious paginationnext dr yvonne greenstreet photo business wire full size small preview thumbnail full size small preview thumbnail january    am eastern standard time collegeville pabusiness wirepfizer inc today announced that dr yvonne greenstreet has been appointed senior vice president and head of medicines development for the specialty care business unit effective february   upon her arrival she will assume global responsibility for leading the advancement of the development portfolio ensuring its alignment with specialty care’s strategic objectives “yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry” said geno germano president and general manager of pfizer’s specialty care business unit “her experience in delivering medicines in challenging markets is noteworthy and she will play an important role in advancing specialty care’s commitment to the eradication remission and relief of serious diseases” dr greenstreet takes over for dr michael berelowitz who is retiring after a distinguished year career at pfizer she will report directly to germano and join his leadership team dr greenstreet joins pfizer after an year career with glaxosmithkline gsk where she most recently was senior vice president and chief of strategy research and development her work spans the rd continuum including clinical development medical affairs health economics outcomes research regulatory affairs and portfolio management at gsk she was responsible for leading the development of small molecules and biologics in several therapeutic areas including musculoskeletal immunologyinflammation gastrointestinal urology ophthalmology and antiinfectives she had also been responsible for clinical development and medical affairs for gsk’s european business before joining gsk dr greenstreet practiced medicine in the united kingdom national health service and gained experience in medicine at a number of leading teaching hospitals in london she holds a degree in medicine from the university of leeds uk and an mba from insead fountainbleau france pfizer inc working together for a healthier world™ at pfizer we apply science and our global resources to improve health and wellbeing at every stage of life we strive to set the standard for quality safety and value in the discovery development and manufacturing of medicines for people and animals our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines as well as nutritional products and many of the worlds bestknown consumer products every day pfizer colleagues work across developed and emerging markets to advance wellness prevention treatments and cures that challenge the most feared diseases of our time consistent with our responsibility as the worlds leading biopharmaceutical company we also collaborate with health care providers governments and local communities to support and expand access to reliable affordable health care around the world for more than  years pfizer has worked to make a difference for all who rely on us to learn more about our commitments please visit us at wwwpfizercom photosmultimedia gallery available httpwwwbusinesswirecomcgibinmmgcgieidlangen contacts pfizer incvictoria davis  contacts pfizer incvictoria davis  search advanced news search advanced news search log in sign up check out yvonne greenstreet one of fast companys most creative people fast companynewslettersubscribefast companyhomepagetechnologyleadershipentertainmentideasvideonewscodesignhomepagecitiesgraphicsinnovation by designinteractiveproductspacescollectionsthe most innovative companiesthe top  companies in entertainment media sports technology and moremost creative peoplemeet this years inspiring leadersinnovation by designa showcase for ingenious design solutionsfuture of philanthropyinside the changing world of givingworld changing ideasnew workplaces new food sources new medicine—even an entirely new economic systemwork smartthe apps tips tactics and brain hacks to help you work smarter instead of harderfastcoworks studioan awardwinning team of journalists designers and videographers who tell brand stories through fast company’s distinctive lenscurrent issuecurrent issuesubscribefollow usadvertisementmost creative peopleyvonne greenstreetsvp and head of medicines development specialty caredr yvonne greenstreet oversees latestage development of some of the most innovative drug research on the planet such as xeljanz a rheumatoid arthritis medication taken orally analysts project that it could be worth  billion to pfizer by 0 she is also passionate about personalized medicine targeted therapies for carriers of particular genesread moreadvertisementadvertisementideasideasnight out for safety and liberation asks how to go beyond policing to keep communities safeideasthis app lets you request mental health help for a homeless person in distressideashow sweden is fast tracking refugees into the workforceentertainmententertainmentnew absolut campaign celebrates the ongoing fight for lgbtq rightsentertainment times obama’s official photographer was trump’s classiest trollentertainment“stranger things ” thriller gucci goes trekkie the top  ads of the weekcodesigncitiesthis woman’s travel photos are better than yours — and she never leaves the houseproductthis airbnb for great architecture is curated by two architectsgraphicsthis photo captures every color in a single twinkling starfast companyideasnight out for safety and liberation asks how to go beyond policing to keep communities safeideasthis app lets you request mental health help for a homeless person in distresstechnologyinside the ico bubble why initial coin offerings have raised more than  billion since january microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext0 about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext0 where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within 0 days ext0 personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext0 personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext0 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies  0 microsoft dr yvonne greenstreet appointed as an independent member of the moelis  company board of directors  thestreet action alerts plus access aapjim cramers best stocks for 0charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for 0 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp 0 market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street dr yvonne greenstreet appointed as an independent member of the moelis  company board of directors business wire feb  0  pm est moelis  company nyse mc a leading global independent investment bank today announced the appointment of dr yvonne greenstreet as an independent member of the board of directors dr greenstreet has over 0 years of experience in the pharmaceutical industry and has held senior roles in research and development strategy commercial development and portfolio management she was formerly senior vice president and head of medicines development for pfizer where she was a member of the specialty business global executive team dr greenstreet also spent  years at glaxosmithkline most recently as senior vice president and chief of strategy for research and development and a member of the corporate portfolio management board she held a variety of positions at glaxosmithkline prior to this including chief medical officer for europe ken moelis chairman and ceo of moelis  company said yvonnes wealth of experience in the pharmaceutical industry and her proven track record as a highly regarded business leader will greatly benefit our firm and our clients we are delighted to welcome her as moelis  companys newest board member dr greenstreet currently serves on the board of directors of pacira pharmaceuticals a specialty pharmaceutical company focused on the development of products for postsurgical pain control the board of directors of advanced accelerator applications a radiopharmaceutical company that develops diagnostic and therapeutic products and the board of directors of indivior a pharmaceutical company that develops products to treat addiction she is also a member of the scientific advisory board of the bill  melinda gates foundation dr greenstreet holds a bachelor of medicine bachelor of surgery from the university of leeds united kingdom and an mba from insead france about moelis  company moelis  company is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base including corporations governments and financial sponsors the firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors moelis  companys experienced professionals advise clients on their most critical decisions including mergers and acquisitions recapitalizations and restructurings and other corporate finance matters the firm serves its clients with  employees based in  offices in north and south america europe the middle east asia and australia for further information please visit wwwmoeliscom if you liked this article you might like cramer a funny thing happened on the way to the selloff this market has diverged from some of its usual patterns jim cramer jun  0  pm edt french billionaire buys christian dior for a whopping b french billionaire bernard arnault will buy out fashion company christian dior cdi for  billion thestreet staff apr  0  pm edt desire to add exposure leads indices higher the fact that many traders werent wellpositioned for mondays move up is helping to create oneway action this morning rev shark apr  0  am edt hsbc wins formal mandate for saudi aramco ipo  report hsbc will advise on saudi aramcos multibillion dollar ipo according to media reports monday potentially increasing chances london could earn a piece of the worlds biggest stock listing martin baccardax apr  0  am edt trending tesla is a cult stock jim cramer says amazon alphabet and a gop failure on healthcare heres where wall street stands when stocks fall and its not their fault cramers mad money recap friday  ipod nano shuffle are dead here are  other discontinued apple products can apple show amazon what earnings should look like advertising partners 0 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers pacira pharmaceuticals inc appoints industry expert yvonne greenstreet to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for 0charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for 0 commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp 0 market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street pacira pharmaceuticals inc appoints industry expert yvonne greenstreet to its board of directors business wire mar  0 0 am est pacira pharmaceuticals inc nasdaqpcrx today announced the appointment of yvonne greenstreet mbchb mba to its board of directors “we are delighted to have yvonne join as our newest board member” said dave stack president chief executive officer and chairman of pacira “we believe that her vast experience working across a diverse range of critical functions at some of the most established names in the industry will support our business activities as we look to expand additional indications for exparel ® and pursue our next depofoambased opportunities” dr yvonne greenstreet has more than 0 years of global experience in the pharmaceutical industry where she has a proven track record as a business leader and drug developer over the course of her career she has successfully obtained approval from the fda and the equivalent regulatory bodies in the uk and eu with respect to ten new drug applications andor marketing authorization applications and has led numerous product launches as senior vice president and head of medicines development at pfizer dr greenstreet was on the global executive team for the  billion specialty business with accountability for a portfolio which included the immunoinflammation vaccine specialty neuroscience and rare disease areas she led the approval of the jak inhibitor xeljanz bringing to market the first of a new class of medicines for patients with rheumatoid arthritis she was also instrumental in growing pfizer’s presence in rare diseases by driving strategy delivering product approvals and securing inlicensed opportunities dr greenstreet was at glaxosmithkine gsk for  years where she was senior vice president and chief of strategy for research and development serving on the corporate executive investment committee she was responsible for enabling strategy development and execution to achieve gsk’s goal of delivering five to seven new medicines per year with increasing returns on investment previously dr greenstreet served in various positions of increasing responsibility at gsk including senior vice president for medicine development where she led the creation of a new global unit that had responsibility for gsk’s musculoskeletal endocrine gastrointestinal ophthalmology and urological disease areas she spearheaded gsk’s entry into immuneinflammation and biologics with the inlicensing of benlysta for patients with lupus and arzerra for patients with chronic lymphocytic leukemia prior to this role she was chief medical officer for gsk europe with responsibility for development and medical affairs of gsk’s entire pipeline and product portfolio in the region if you liked this article you might like biotech premarket movers editas amphastar aratana pacira editas medicine amphastar pharmaceuticals aratana therapeutics and pacira pharmaceuticals were among the biotech stock movers in premarket trading on tuesday armie margaret lee mar  0  am edt pacira pharmaceuticals tops q earnings expectations pacira pcrx reported mixed fourth quarter results tony owusu mar  0  am est biotech premarket movers pacira clearside biomedical and organovo pacira pharmaceuticals clearside biomedical and organovo holdings are among the premarket biotech movers on wednesday armie margaret lee jan  0  am est bullish and bearish reversals in the market these companies show signs of a change of direction guy ortmann jan  0  pm est trending tesla is a cult stock jim cramer says when stocks fall and its not their fault cramers mad money recap friday  amazon alphabet and a gop failure on healthcare heres where wall street stands ipod nano shuffle are dead here are  other discontinued apple products ftc seen as set to block rite aid deal advertising partners 0 thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers alnylam pharmaceuticals inc  alnylam expands and strengthens management team as it plans for commercialization alnylam about alnylam about rnai delivery of rnai therapeutics scientific leadership strategic alliances intellectual property alnylam × ttr amyloidosis fap ttr amyloidosis fac hemophilia complementmediated disease porphyria cardiometabolic disease alpha antitrypsin deficiency hepatitis b virus infection betathalassemia and iron overload disorders other pipeline programs our story our culture careers management board of directors scientific advisory board               share this on delicious digg facebook linkedin twitter what is this alnylam expands and strengthens management team as it plans for commercialization 0  dr yvonne greenstreet and dr emmanuel dulac join alnylam bringing significant product strategy portfolio management and commercialization experience  cambridge massbusiness wire alnylam pharmaceuticals inc nasdaqalny the leading rnai therapeutics company announced today two key appointments to its senior leadership team expanding the breadth of talent and experience as the company prepares for commercialization of its pipeline and global expansion dr yvonne greenstreet has joined as executive vice president chief operating officer and dr emmanuel dulac as senior vice president chief commercial officer both drs greenstreet and dulac offer decades of life science experience in drug development and successfully launching medicines to the market in areas of unmet needs in addition both have worked in global capacities and have supported execution on strategies involving substantial organizational growth barry greene will continue to serve as the companys president with our rapid pipeline growth and maturity toward commercial stages were focused on building our team to achieve our alnylam  goals in this regard the appointments of yvonne and emmanuel significantly bolster the depth of product experience and commercial expertise in our growing organization said john maraganore phd chief executive officer of alnylam im confident that their insight and leadership will help us realize our mission of building a toptier biopharmaceutical company founded on rnai and speed the path of bringing potentially life changing new therapies to patients through innovative drug development commercial and patient access strategies dr greenstreet will report to john maraganore and will have responsibility for leading the companys multidisciplinary product teams from early development through and during commercialization in this capacity yvonne will have responsibility for the global general managers currently in place for attr programs fitusiran and alncc program leaders and the program management team which are all focused on progressing development pipeline programs through to launch and commercialization additionally she will be responsible for leading the alliance management team primarily focused on our partnership with sanofi genzyme its a pleasure to join the team at alnylam at such an important time in the companys evolution where rnai therapeutics are advancing toward commercial stages said dr greenstreet alnylams pipeline is one of the most exciting in the industry and im thrilled to be part of a team pioneering new medicines to meet unmet needs for patients this is a vitally important mission where i believe i can add significant value dr greenstreet brings  years of global experience in the pharmaceutical industry where she has been in senior roles in research and development strategy and portfolio management and has successfully led product development and commercialization teams in a wide range of therapy areas bringing new medicines to patients dr greenstreet was previously senior vice president and head of medicines development at pfizer with accountability for a portfolio that included the immunoinflammation vaccines specialty neuroscience and rare disease areas prior to pfizer she held roles of increasing responsibility at glaxosmithkline including senior vice president and chief of strategy for research and development senior vice president for medicines development and chief medical officer for europe dr greenstreet holds a bachelor of medicine bachelor of surgery from the university of leeds uk and master of business administration mba from insead france she serves as an advisor and board member for several public companies and also serves on the scientific advisory committee for the bill and melinda gates foundation dr dulac will report to barry greene and will be responsible for establishing alnylams global commercial footprint he will lead the development of the global commercial expertise area building global commercial capabilities including support of patients post product launch and building the us commercial operations i feel fortunate to be joining alnylam at a time when we have the opportunity to develop and shape our commercial strategies for a ground breaking new approach to treating disease rnai therapeutics have now passed the proof of concept stage and have the potential to profoundly transform patients lives it gives us the potential to target many unserved diseases with an extremely precise medicine and an uncommonly long duration of activity i feel privileged to have been entrusted to build and lead a toptier organization that will attract the best talent in the industry and bring these truly differentiated medicines to patients said dr dulac dr dulac brings to alnylam more than 0 years of international experience in the biotech and pharmaceutical industry he joins the company from shire where he was senior vice president head of the rare disease business unit prior to shire emmanuel held various roles of increasing responsibility at sanofi abbott and novartis in global regional and local functions during his career he successfully launched six brands led two blockbuster drugs globally and built large sales organizations innovative patient services and strong marketing and market access teams he graduated from the university of paris xi with a doctorate in pharmacology pharmd phd and completed an mba from the essec school in paris about rnai rnai rna interference is a revolution in biology representing a breakthrough in understanding how genes are turned on and off in cells and a completely new approach to drug discovery and development its discovery has been heralded as a major scientific breakthrough that happens once every decade or so and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the  nobel prize for physiology or medicine rnai is a natural process of gene silencing that occurs in organisms ranging from plants to mammals by harnessing the natural biological process of rnai occurring in our cells the creation of a major new class of medicines known as rnai therapeutics is on the horizon small interfering rna sirna the molecules that mediate rnai and comprise alnylams rnai therapeutic platform target the cause of diseases by potently silencing specific mrnas thereby preventing diseasecausing proteins from being made rnai therapeutics have the potential to treat disease and help patients in a fundamentally new way about alnylam pharmaceuticals alnylam is a biopharmaceutical company developing novel therapeutics based on rna interference or rnai the company is leading the translation of rnai as a new class of innovative medicines alnylams pipeline of investigational rnai therapeutics is focused in  strategic therapeutic areas stars genetic medicines with a broad pipeline of rnai therapeutics for the treatment of rare diseases cardiometabolic disease with a pipeline of rnai therapeutics toward genetically validated liverexpressed disease targets for unmet needs in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of rnai therapeutics that address the major global health challenges of hepatic infectious diseases in early 0 alnylam launched its alnylam  guidance for the advancement and commercialization of rnai therapeutics as a whole new class of innovative medicines specifically by the end of  alnylam expects to achieve a company profile with  marketed products  rnai therapeutic clinical programs  including  in late stages of development  across its  stars the companys demonstrated commitment to rnai therapeutics has enabled it to form major alliances with leading companies including ionis novartis roche takeda merck monsanto the medicines company and sanofi genzyme in addition alnylam holds an equity position in regulus therapeutics inc a company focused on discovery development and commercialization of microrna therapeutics alnylam scientists and collaborators have published their research on rnai therapeutics in over  peerreviewed papers including many in the worlds top scientific journals such as nature nature medicine nature biotechnology cell new england journal of medicine and the lancet founded in  alnylam maintains headquarters in cambridge massachusetts for more information about alnylams pipeline of investigational rnai therapeutics please visit wwwalnylamcom alnylam forwardlooking statements various statements in this release concerning alnylams future expectations plans and prospects including without limitation alnylams views with respect to the potential for rnai therapeutics its expectations regarding its star pipeline growth strategy and its alnylam  guidance for the advancement and commercialization of rnai therapeutics constitute forwardlooking statements for the purposes of the safe harbor provisions under the private securities litigation reform act of  actual results and future plans may differ materially from those indicated by these forwardlooking statements as a result of various important risks uncertainties and other factors including without limitation alnylams ability to discover and develop novel drug candidates and delivery approaches successfully demonstrate the efficacy and safety of its product candidates the preclinical and clinical results for its product candidates which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all actions or advice of regulatory agencies which may affect the design initiation timing continuation andor progress of clinical trials or result in the need for additional preclinical andor clinical testing delays interruptions or failures in the manufacture and supply of our product candidates obtaining maintaining and protecting intellectual property alnylams ability to enforce its intellectual property rights against third parties and defend its patent portfolio against challenges from third parties obtaining and maintaining regulatory approval pricing and reimbursement for products progress in establishing a commercial and exunited states infrastructure competition from others using technology similar to alnylams and others developing products for similar uses alnylams ability to manage its growth and operating expenses obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives alnylams dependence on third parties for development manufacture and distribution of products the outcome of litigation the risk of government investigations and unexpected expenditures as well as those risks more fully discussed in the risk factors filed with alnylams most recent quarterly report on form q filed with the securities and exchange commission sec and in other filings that alnylam makes with the sec in addition any forwardlooking statements represent alnylams views only as of today and should not be relied upon as representing its views as of any subsequent date alnylam explicitly disclaims any obligation except to the extent required by law to update any forwardlooking statements view source version on businesswirecom httpwwwbusinesswirecomnewshome0en alnylam pharmaceuticals incinvestors and mediachristine regan lindenboom 0orinvestorsjosh brodsky  source alnylam pharmaceuticals inc news provided by acquire media search search recent press releases 00 alnylam to host fourth annual rnai roundtable webcast series 00 alnylam and sanofi genzyme report positive results from ongoing phase  openlabel extension study with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors 000 alnylam and sanofi genzyme initiate atlas phase  program with investigational rnai therapeutic fitusiran in patients with hemophilia a and b with or without inhibitors view all releases nasdaq alny common price  change    volume  data as of  pm et on 00minimum 0 minute delay learn more dr yvonne greenstreet joins pfizer as senior vice president and head of medicines development specialty care business unit  pfizer one of the worlds premier biopharmaceutical companies sorry you need to enable javascript to visit this website careersworking heremission  purpose culture diversity  inclusion career growth  colleague development compensation  benefits ensuring corporate responsibility search jobs student  early careerpostdoctoral program us summer student worker program opportunities for veterans pfizercom our hiring  recruiting processfrequently asked questions tips for interviewing at pfizer connect with us investorsinvestors overviewwhy invest  our story prospective investors fact sheet events  presentations financialsquarterly reports annual reports sec filings interactive data filings investor news stock informationhistorical stock chart  data investment calculator historical price lookup dividend  split history stock faqs governanceboard committees and charters the pfizer board policies corporate governance faqs contact our directors shareholder servicesstock faqs cost basis calculator advisory information newspress release archive press statements company press kit vaccines press kit get old press kit pfizer oncology press kit ra narrative frequently requested info contact media relations partnerspartnership highlights contacts events pfizer is attending submit your opportunities biopharmaceuticals consumer healthcare core therapeutic areas innovation research  development venture investmentsour portfolio health professionals connect with usemail faq privacy policy youtube twitter facebook linkedin instagram en argentina australia austria belgium brazil canada china colombia czech republic denmark finland france germany greece hong kong hungary india indonesia ireland israel italy japan korea malaysiasingapore mexico netherlands new zealand norway pakistan philippines poland portugal romania russia slovakia south africa spain sweden switzerland taiwan thailand turkey united kingdom ukraine your health healthy living brain  nervous system cardiovascular health digestive health healthier aging living tobacco free men’s health mental health nutrition  fitness pediatric health respiratory health skin health vaccines  prevention women’s health disease  conditions cancer cardiovascular diseases  conditions diabetes  metabolic disorders immune system diseases  conditions infections  infectious diseases neurological diseases  conditions rare disease skin diseases  condition vaccinerelated conditions managing your health caregiving evaluating health information tracking your health your medicines hot topics hot topics the smoking epidemic a snapshot our science therapeutic areas metabolic disease  cardiovascular risk inflammation  immunology neuroscience  pain oncology rare disease vaccines product pipeline clinical trials what are clinical trials how clinical trials are conducted clinical innovation find a trial trial data  results post marketing commitments rd platforms biosimilars gene therapy medicinal sciences precision medicine collaboration collaboration ecosystem centers for therapeutic innovation competitive grants compound transfer program investigatorinitiated research rd collaborations research sites hot topics learn more vaccines to fight sugarcoated bacteria our people meet the experts scientists cardiovascular  metabolic disease immunology  inflammation neuroscience  pain oncology rare disease vaccines medical professionals the journey leadership executives board members company fact sheet diverse perspectives diversity  inclusion supplier diversity hot topics aspen ideas scholar austin huang aspen ideas scholar jackie conde our purpose responsibility individual voices building healthcare capacity expanding access to medicine corporate citizenship global institutions and partnerships reporting trends and progress protecting the environment pfizer’s green journey environment health  safety product stewardship positions on health policies ready for cures value of medicines how does pfizer price medicines policy positions transparency working with health care professionals sales and marketing compliance corporate compliance code of conduct patient assistance programs pfizer rx pathways goverment programs grants independent grants transparency in grants contributions  partnerships healthcare charitable contributions special charity events lobbying  political contributions hot topics read more our products product listing how drugs are made branded vs generic biologics  biosimilars commitment to quality distributors pfizer distributors greenstone distributors medicine and safety medicine safety medicine safety education reporting adverse events unused medicines sharps disposal counterfeiting safety data sheets medical information contacts hot topics the end of smallpox before it became a medicine you are herenews  dr yvonne greenstreet joins pfizer as senior vice president and head of medicines development specialty care business unit dr yvonne greenstreet joins pfizer as senior vice president and head of medicines development specialty care business unit sunday january 0   0pmesther experience in delivering medicines in challenging markets is noteworthy and she will play an important role in advancing specialty care’s commitment to the eradication remission and relief of serious diseases business wirepfizer inc today announced that dr yvonne greenstreet has been appointed senior vice president and head of medicines development for the specialty care business unit effective february   upon her arrival she will assume global responsibility for leading the advancement of the development portfolio ensuring its alignment with specialty care’s strategic objectives “yvonne has a strong track record of leadership and outstanding results during her career in the biopharmaceutical industry” said geno germano president and general manager of pfizer’s specialty care business unit “her experience in delivering medicines in challenging markets is noteworthy and she will play an important role in advancing specialty care’s commitment to the eradication remission and relief of serious diseases” dr greenstreet takes over for dr michael berelowitz who is retiring after a distinguished year career at pfizer she will report directly to germano and join his leadership team dr greenstreet joins pfizer after an year career with glaxosmithkline gsk where she most recently was senior vice president and chief of strategy research and development her work spans the rd continuum including clinical development medical affairs health economics outcomes research regulatory affairs and portfolio management at gsk she was responsible for leading the development of small molecules and biologics in several therapeutic areas including musculoskeletal immunologyinflammation gastrointestinal urology ophthalmology and antiinfectives she had also been responsible for clinical development and medical affairs for gsk’s european business before joining gsk dr greenstreet practiced medicine in the united kingdom national health service and gained experience in medicine at a number of leading teaching hospitals in london she holds a degree in medicine from the university of leeds uk and an mba from insead fountainbleau france pfizer inc working together for a healthier world™ at pfizer we apply science and our global resources to improve health and wellbeing at every stage of life we strive to set the standard for quality safety and value in the discovery development and manufacturing of medicines for people and animals our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines as well as nutritional products and many of the worlds bestknown consumer products every day pfizer colleagues work across developed and emerging markets to advance wellness prevention treatments and cures that challenge the most feared diseases of our time consistent with our responsibility as the worlds leading biopharmaceutical company we also collaborate with health care providers governments and local communities to support and expand access to reliable affordable health care around the world for more than  years pfizer has worked to make a difference for all who rely on us to learn more about our commitments please visit us at wwwpfizercom photosmultimedia gallery available httpwwwbusinesswirecomcgibinmmgcgieidlangen   multimedia files download all files dr yvonne greenstreet photo business wire download download viewimage  kb download high resolution  mb download thumbnail  kb download web ready  kb   contact  pfizer inc victoria davis        share yvonne greenstreet  board of directors  pacira pharmaceuticals inc  science center drivesuite san diego ca     sylvan wayparsippany nj   0 about pacira overview management board of directors  products  pipeline exparel® about exparel® partnering depocyte® about depocyte® strategic partnering clinical trials  platform about depofoam® how it works applications partnership opportunities grants  investors  media company overview corporate governance stock information research coverage press releases sec filings legal resolution overview event calendar online investor kit email alerts information request  careers why pacira opportunities overview management board of directors board of directors yvonne greenstreet mbchb mbaalnylam pharmaceuticals inc yvonne greenstreet has served as executive vice president and chief operating officer of alnylam pharmaceuticals a leading rnai therapeutics company since september 0 prior to joining alnylam dr greenstreet was senior vice president and head of medicines development at pfizer dr greenstreet was also at glaxosmithkline gsk for  years as senior vice president and chief of strategy for research and development dr greenstreet previously served in various positions of increasing responsibility at gsk including senior vice president for medicine development in which she led the creation of a new global unit which had responsibility for gsks musculoskeletal endocrine gastrointestinal ophthalmology and urological disease areas prior to this role she was chief medical officer for gsk europe with responsibility for development and medical affairs of gsk’s entire pipeline and product portfolio in the region dr greenstreet currently serves on the boards of indivior plc and advanced accelerator applications sa as well as on the scientific advisory board of the bill and melinda gates foundation dr greenstreet trained as a physician and earned her medical degree from leeds university in the uk and her mba from insead france quick links corporate presentation news exparel about management grants clinical trials legal resolution overview board of directors david stackpacira pharmaceuticals paul hastings lead directoroncomed pharmaceuticals laura bregeformer ceo of nodality inc yvonne greenstreet mbchb mbaalnylam pharmaceuticals inc mark kronenfeld mdmaimonides medical center john p longenecker phd gary w pace phd andreas wicki phdhbm healthcare investments ag dennis l wingerformer cfo of applera corporationaccuray incorporatednektar therapeutics contact us legal site map  0 pacira pharmaceuticals yvonne greenstreet  indivior  this site uses cookies by continuing to browse the site without disabling them you consent to our use of cookies to learn more about the types of cookies we use please view our cookie policy continue using the site about  history executive committee the board grants yvonne greenstreet nonexecutive director yvonne is currently chief operating officer at alnylam pharmaceuticals a biopharmaceutical company developing novel therapeutics based on rna interference or rnai  yvonne has more than 0 years of global experience in the pharmaceutical industry spanning research and development strategy and commercial development yvonne serves on the boards of directors of pacira pharmaceuticals and advanced accelerator applications she is also on the advisory board of the bill and melinda gates foundation between  and 0 yvonne was senior vice president and head of medicines development at pfizer and a member of the global executive team for the  billion specialty business with accountability for a portfolio that included the immunoinflammation vaccine specialty neuroscience and rare disease areas prior to pfizer she was at glaxo smithkline plc for  years where she was senior vice president and chief of strategy for research and development serving on the corporate executive investment committee she was responsible for enabling strategy development and execution to achieve gsk’s goal of delivering five to seven new medicines per year while reducing research and development spend yvonne had previously been in various positions of increasing responsibility at gsk including senior vice president for medicine development and chief medical officer for europe yvonne trained as a physician and earned her medical degree from leeds university in the uk and her mba from insead france chair of the science  policy committee member of the audit committee you are now leaving indiviorcom to visit suboxonecom a us product site intended for us residents and healthcare professionals continue    return you are now leaving indiviorcom continue    return